Opus Genetics Inherited Retinal Disease Programs Featured
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company…
Opus Genetics’ BEST1 Gene Therapy IND Cleared by FDA
Opus Genetics (Nasdaq: IRD) has received FDA clearance for its…
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
Opus Genetics, Inc. – Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data…
Opus Genetics and the Global RDH12 Alliance Partner to
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE…